Robinson RG, Smith SM, Wolkenberg SE, et. al. Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates. ACS Chem Neurosci. 2012 Feb 15;3(2):129-40. doi: 10.1021/cn200109w. Epub 2011 Nov 14. (PMID: 22860182).
Millan M, Agid Y, Brune M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Reviews, 2012; 11: 141-168.
Fava M, Rosenbaum J, et al. Open Study of the Catechol-O-Methyltransferase Inhibitor Tolcapone in Major Depressive Disorder. J Clinical Psychopharmacol, Aug; 19(4): 329-335.
Investing in Mental Health, Department of Mental Health and Substance Abuse, World Health Organization; 2003 ISBN 92 4 156257.
Grant J, Odlaug B. et al. A proof of concept study of tolcapone for pathological gambling: Relationships with COMT genotype and brain activation. European Neuropsychopharm, 2013; 23: 1587-1596.
Apud J, Weinberger D. Treatment of Cognitive Deficits Associated with Schizophrenia: Potential Role of Catechol-O-Methyltransferase Inhibitors. CNS Drugs, 2007; 21 (7): 535-557.
Disclaimer: These links are being provided as a convenience and for informational purposes only. The views, opinions and conclusions expressed in the links above are those of the authors and do not necessarily reflect the views, opinions and conclusions of the Company. The Company bears no responsibility for the accuracy, legality or content of any external links.